These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 35861919)

  • 21. An evaluation of von Willebrand factor (recombinant) therapy for adult patients living with severe type 3 von Willebrand disease.
    Hancock JM; Escobar MA
    Expert Rev Hematol; 2023 Mar; 16(3):157-161. PubMed ID: 36861346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease.
    Franchini M; Mannucci PM
    Expert Rev Hematol; 2016 Sep; 9(9):825-30. PubMed ID: 27427955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How I manage severe von Willebrand disease.
    Leebeek FWG; Atiq F
    Br J Haematol; 2019 Nov; 187(4):418-430. PubMed ID: 31498884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of current perioperative management with Haemate
    Hazendonk HCAM; Heijdra JM; de Jager NCB; Veerman HC; Boender J; van Moort I; Mathôt RAA; Meijer K; Laros-van Gorkom BAP; Eikenboom J; Fijnvandraat K; Leebeek FWG; Cnossen MH;
    Haemophilia; 2018 May; 24(3):460-470. PubMed ID: 29573506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS-IPS, an international and collaborative cross-sectional study.
    Tosetto A; Badiee Z; Baghaipour MR; Baronciani L; Battle J; Berntorp E; Bodó I; Budde U; Castaman G; Eikenboom JCJ; Eshghi P; Ettorre C; Goodeve A; Goudemand J; Hay CRM; Hoorfar H; Karimi M; Keikhaei B; Lassila R; Leebeek FWG; Lopez Fernandez MF; Mannucci PM; Mazzucconi MG; Morfini M; Oldenburg J; Peake I; Parra Lòpez R; Peyvandi F; Schneppenheim R; Tiede A; Toogeh G; Trossaert M; Zekavat O; Zetterberg EMK; Federici AB
    J Thromb Haemost; 2020 Sep; 18(9):2145-2154. PubMed ID: 32379400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical diagnosis of von Willebrand disease.
    Federici AB
    Haemophilia; 2004 Oct; 10 Suppl 4():169-76. PubMed ID: 15479393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New treatment approaches to von Willebrand disease.
    Lavin M; O'Donnell JS
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):683-689. PubMed ID: 27913547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of von Willebrand disease: a survey on current clinical practice from the haemophilia centres of North America.
    Cohen AJ; Kessler CM; Ewenstein BM;
    Haemophilia; 2001 May; 7(3):235-41. PubMed ID: 11380626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnosis and management of von Willebrand disease in Spain.
    Batlle J; Perez-Rodriguez A; Pinto JC; Fraga EL; Rodriguez-Trillo Tch A; Fernanda Lopez-Fernandez M
    Semin Thromb Hemost; 2011 Jul; 37(5):503-10. PubMed ID: 22102193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bleeding-related hospitalization in patients with von Willebrand disease and the impact of prophylaxis: Results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network.
    Holm E; Carlsson KS; Lövdahl S; Lail AE; Abshire TC; Berntorp E
    Haemophilia; 2018 Jul; 24(4):628-633. PubMed ID: 29626372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical significance of slightly reduced von Willebrand factor activity.
    Bykowska K; Ceglarek B
    Pol Arch Intern Med; 2020 Mar; 130(3):225-231. PubMed ID: 31990275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Closing the gap - detection of clinically relevant von Willebrand disease in emergency settings through an improved algorithm based on rotational Thromboelastometry.
    Topf HG; Strasser ER; Breuer G; Rascher W; Rauh M; Fahlbusch FB
    BMC Anesthesiol; 2019 Jan; 19(1):10. PubMed ID: 30630422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN).
    Abshire TC; Federici AB; Alvárez MT; Bowen J; Carcao MD; Cox Gill J; Key NS; Kouides PA; Kurnik K; Lail AE; Leebeek FW; Makris M; Mannucci PM; Winikoff R; Berntorp E;
    Haemophilia; 2013 Jan; 19(1):76-81. PubMed ID: 22823000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Von Willebrand disease - the 'Dos' and 'Don'ts' in surgery.
    Miesbach W; Berntorp E
    Eur J Haematol; 2017 Feb; 98(2):121-127. PubMed ID: 27622750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.
    Federici AB; Baudo F; Caracciolo C; Mancuso G; Mazzucconi MG; Musso R; Schinco PC; Targhetta R; Mannuccio Mannucci P
    Haemophilia; 2002 Nov; 8(6):761-7. PubMed ID: 12410644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A need to increase von Willebrand disease awareness: vwdtest.com - A global initiative to help address this gap.
    Corrales-Medina FF; Federici AB; Srivastava A; Dougall A; Millar CM; Roberts JC; Jaffray J; Berntorp E
    Blood Rev; 2023 Mar; 58():101018. PubMed ID: 36210240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of emicizumab in von Willebrand disease (VWD) patients with and without alloantibodies to von Willebrand factor (VWF): Report of two cases and review of literature.
    Shanmukhaiah C; Jijina F; Kannan S; Pai NG; Kulkarni B; Khuba SV; Shaikh M; Joshi A; Phatale R; Apte S
    Haemophilia; 2022 Mar; 28(2):286-291. PubMed ID: 35014121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Diagnosis and management of von Willebrand disease].
    Higasa S; Tokugawa T; Sawada A
    Rinsho Ketsueki; 2018; 59(10):2222-2232. PubMed ID: 30305529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.